leisure time -WSS

leisure time

author：leisure time 2025-10-01 13:58:48 - browse：355

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

WSS

ADA: All diabetes patients should be screened for liver condition

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Texas Department of Public Safety speaks out on migrant abuse allegations

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Brazil's Jair Bolsonaro is barred from running for office until 2030

Study identifies new proteins linked to dementia risk 25 years later

Wikipedia

leisure time

leisure time

Medicare details structure of new drug price negotiation program

UnitedHealth wins $3.3 billion takeover of Amedisys

Walensky prepares to leave CDC — and Congress — behind

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Psychedelics group wrestles with new pharma identity

Study identifies new proteins linked to dementia risk 25 years later

As demand for Covid shots wanes, Moderna seeks its next success

Mass General totes up its waste in a move to tackle climate change

ChatGPT in medicine: STAT answers readers' burning questions

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Wikipedia

Why Congress must ban federal programs from using QALYs

Tocagen's brain cancer gene therapy trial continues. Investors worry

I learned firsthand about improving diversity in clinical trials

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Why Congress must ban federal programs from using QALYs

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Wikipedia

explore

knowledge

leisure time